MedPath

Investigation about the diabetes treatment satisfaction and the usability of insulin injector by the change to insulin glargine U-300 in type 1 and type2 diabetes patients under treatment with sustained-release dissolution insuli

Not Applicable
Conditions
Type 1 diabetes mellitus and type 2 diabetes mellitus
Registration Number
JPRN-UMIN000024122
Lead Sponsor
Saitama Medical University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1) The patients are pregnant or have possibility of pregnancy. 2) The patients with hypersensitivity for Insulin Glargin U-300. 3) The patients with serious complications and considered inappropriate to participate in this study by the doctor in charge. 4) The patients whose HbA1c fluctuated more than 1.0% within the past three months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
usability and satisfaction of the change to insulin glargine U-300 by using Questionnaire
Secondary Outcome Measures
NameTimeMethod
Change in bodyweight,insulin dose,glucose (fasting),HbA1c,GA,CPR,TG,TC,LDL-C,HDL-C,ALT(GPT),AST(GOT),GTP,Uric acid,Creatinine,Urine microalbumin,blood pressure,adverse events
© Copyright 2025. All Rights Reserved by MedPath